Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor

International Journal of Pharmaceutics

Volumn 339, Issue 1-2, 2007, Pages 139-147

  Agarwal, Sheetal ^a   Pal, Dhananjay ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Breast cancer resistance protein (BCRP); Efflux ratio (ER); Lopinavir (LVR); MDCKII Bcrp1; MDCKII MDR1; MDCKII MRP1; MDCKII MRP2; MDCKII WT; Multidrug resistance protein (MRP); P glycoprotein (P gp); Permeability; Transport; Uptake

Indexed keywords

CARRIER PROTEIN; COMPLEMENTARY DNA; ELACRIDAR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; LOPINAVIR; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; P GLYCOPROTEIN 4008; PROTEIN BCRP1; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VERLUKAST;

ANIMAL CELL; ARTICLE; CELL LINE; CELL POLARITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG TRANSPORT; GENETIC TRANSFECTION; INTRACELLULAR TRANSPORT; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; DOGS; HIV PROTEASE INHIBITORS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PERMEABILITY; PROPIONATES; PYRIMIDINONES; QUINOLINES; TRITIUM;

EID: 34250863207     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.02.036     Document Type: Article

References (58)

1. Bachmeier C.J., Spitzenberger T.J., Elmquist W.F., and Miller D.W. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm. Res. 22 (2005) 1259-1268
2. Bates S.E., Robey R., Miyake K., Rao K., Ross D.D., and Litman T. The role of half-transporters in multidrug resistance. J. Bioenerg. Biomembr. 33 (2001) 503-511
3. Borst P., Schinkel A.H., Smit J.J., Wagenaar E., Van Deemter L., Smith A.J., Eijdems E.W., Baas F., and Zaman G.J. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol. Ther. 60 (1993) 289-299
4. Borst P., Evers R., Kool M., and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92 (2000) 1295-1302
5. Chen Z.S., Kawabe T., Ono M., Aoki S., Sumizawa T., Furukawa T., Uchiumi T., Wada M., Kuwano M., and Akiyama S.I. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol. Pharmacol. 56 (1999) 1219-1228
6. Choo E.F., Leake B., Wandel C., Imamura H., Wood A.J., Wilkinson G.R., and Kim R.B. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28 (2000) 655-660
7. Danner S.A., Carr A., Leonard J.M., Lehman L.M., Gudiol F., Gonzales J., Raventos A., Rubio R., Bouza E., Pintado V., et al., European-Australian Collaborative Ritonavir Study Group. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333 (1995) 1528-1533
8. De Bruin M., Miyake K., Litman T., Robey R., and Bates S.E. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 146 (1999) 117-126
9. Doyle L.A., and Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22 (2003) 7340-7358
10. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., and Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 15665-15670
11. Eisenblatter T., Huwel S., and Galla H.J. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res. 971 (2003) 221-231
12. Ejendal K.F., and Hrycyna C.A. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr. Protein. Pept. Sci. 3 (2002) 503-511
13. Endicott J.A., and Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58 (1989) 137-171
14. Evers R., Cnubben N.H., Wijnholds J., Van Deemter L., Van Bladeren P.J., and Borst P. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett. 419 (1997) 112-116
15. Evers R., Kool M., Van Deemter L., Janssen H., Calafat J., Oomen L.C., Paulusma C.C., Oude Elferink R.P., Baas F., Schinkel A.H., and Borst P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 101 (1998) 1310-1319
16. Evers R., De Haas M., Sparidans R., Beijnen J., Wielinga P.R., Lankelma J., and Borst P. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer 83 (2000) 375-383
17. Gekeler V., Ise W., Sanders K.H., Ulrich W.R., and Beck J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun. 208 (1995) 345-352
18. Germann U.A., Pastan I., and Gottesman M.M. P-glycoproteins: mediators of multidrug resistance. Semin. Cell Biol. 4 (1993) 63-76
19. Gimenez F., Fernandez C., and Mabondzo A. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J. Acquir. Immune Defic. Syndr. 36 (2004) 649-658
20. Gupta A., Zhang Y., Unadkat J.D., and Mao Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther. 310 (2004) 334-341
21. Hipfner D.R., Deeley R.G., and Cole S.P. Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1461 (1999) 359-376
22. Huisman M.T., Smit J.W., Wiltshire H.R., Hoetelmans R.M., Beijnen J.H., and Schinkel A.H. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 59 (2001) 806-813
23. Huisman M.T., Smit J.W., Crommentuyn K.M., Zelcer N., Wiltshire H.R., Beijnen J.H., and Schinkel A.H. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16 (2002) 2295-2301
24. Hunter J., Jepson M.A., Tsuruo T., Simmons N.L., and Hirst B.H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 268 (1993) 14991-14997
25. Hurst M., and Faulds D. Lopinavir. Drugs 60 (2000) 1371-1379 discussion 1380-1371
26. Hyafil F., Vergely C., Du Vignaud P., and Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53 (1993) 4595-4602
27. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H., and Schinkel A.H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92 (2000) 1651-1656
28. Katragadda S., Budda B., Anand B.S., and Mitra A.K. Role of efflux pumps and metabolising enzymes in drug delivery. Expert Opin. Drug Deliv. 2 (2005) 683-705
29. Kempf D.J., Marsh K.C., Denissen J.F., McDonald E., Vasavanonda S., Flentge C.A., Green B.E., Fino L., Park C.H., Kong X.P., et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. U.S.A 92 (1995) 2484-2488
30. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., and Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101 (1998) 289-294
31. Kool M., Van der Linden M., De Haas M., Scheffer G.L., De Vree J.M., Smith A.J., Jansen G., Peters G.J., Ponne N., Scheper R.J., Elferink R.P., Baas F., and Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. U.S.A 96 (1999) 6914-6919
32. Kruh G.D., and Belinsky M.G. The MRP family of drug efflux pumps. Oncogene 22 (2003) 7537-7552
33. Kumar G.N., Dykstra J., Roberts E.M., Jayanti V.K., Hickman D., Uchic J., Yao Y., Surber B., Thomas S., and Granneman G.R. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab. Dispos. 27 (1999) 902-908
34. Kumar G.N., Jayanti V.K., Johnson M.K., Uchic J., Thomas S., Lee R.D., Grabowski B.A., Sham H.L., Kempf D.J., Denissen J.F., Marsh K.C., Sun E., and Roberts S.A. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm. Res. 21 (2004) 1622-1630
35. Lee B.D., Li Z., French K.J., Zhuang Y., Xia Z., and Smith C.D. Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. J. Med. Chem. 47 (2004) 1413-1422
36. Litman T., Brangi M., Hudson E., Fetsch P., Abati A., Ross D.D., Miyake K., Resau J.H., and Bates S.E. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. 113 Pt 11 (2000) 2011-2021
37. Litman T., Druley T.E., Stein W.D., and Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci. 58 (2001) 931-959
38. Miller J.L. FDA approves new protease inhibitor for HIV infection. Am. J. Health Syst. Pharm. 57 (2000) 1942
39. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
40. Pal D., and Mitra A.K. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 78 (2006) 2131-2145
41. Patick A.K., Mo H., Markowitz M., Appelt K., Wu B., Musick L., Kalish V., Kaldor S., Reich S., Ho D., and Webber S. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40 (1996) 292-297
42. Polli J.W., Jarrett J.L., Studenberg S.D., Humphreys J.E., Dennis S.W., Brouwer K.R., and Woolley J.L. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16 (1999) 1206-1212
43. Roberts N.A., Martin J.A., Kinchington D., Broadhurst A.V., Craig J.C., Duncan I.B., Galpin S.A., Handa B.K., Kay J., Krohn A., et al. Rational design of peptide-based HIV proteinase inhibitors. Science 248 (1990) 358-361
44. Shukla S., Robey R.W., Bates S.E., and Ambudkar S.V. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 45 (2006) 8940-8951
45. Smit J.W., Huisman M.T., Van Tellingen O., Wiltshire H.R., and Schinkel A.H. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. 104 (1999) 1441-1447
46. Taipalensuu J., Tornblom H., Lindberg G., Einarsson C., Sjoqvist F., Melhus H., Garberg P., Sjostrom B., Lundgren B., and Artursson P. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 299 (2001) 164-170
47. Vacca J.P., Dorsey B.D., Schleif W.A., Levin R.B., McDaniel S.L., Darke P.L., Zugay J., Quintero J.C., Blahy O.M., Roth E., et al. L-735, 524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4096-4100
48. Van Asperen J., Van Tellingen O., Sparreboom A., Schinkel A.H., Borst P., Nooijen W.J., and Beijnen J.H. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer 76 (1997) 1181-1183
49. Van Aubel R.A., Van Kuijck M.A., Koenderink J.B., Deen P.M., Van Os C.H., and Russel F.G. Adenosine triphosphate-dependent transport of anionic conjugates by the rabbit multidrug resistance-associated protein Mrp2 expressed in insect cells. Mol. Pharmacol. 53 (1998) 1062-1067
50. Vishnuvardhan D., Moltke L.L., Richert C., and Greenblatt D.J. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS 17 (2003) 1092-1094
51. Wacher V.J., Wu C.Y., and Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13 (1995) 129-134
52. Wacher V.J., Silverman J.A., Zhang Y., and Benet L.Z. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87 (1998) 1322-1330
53. Wacher V.J., Salphati L., and Benet L.Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 46 (2001) 89-102
54. Wallstab A., Koester M., Bohme M., and Keppler D. Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918. Br. J. Cancer 79 (1999) 1053-1060
55. Wijnholds J., Mol C.A., Van Deemter L., De Haas M., Scheffer G.L., Baas F., Beijnen J.H., Scheper R.J., Hatse S., De Clercq E., Balzarini J., and Borst P. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7476-7481
56. Williams G.C., and Sinko P.J. Oral absorption of the HIV protease inhibitors: a current update. Adv. Drug Deliv. Rev. 39 (1999) 211-238
57. Williams G.C., Liu A., Knipp G., and Sinko P.J. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob. Agents Chemother. 46 (2002) 3456-3462
58. Woodahl E.L., Yang Z., Bui T., Shen D.D., and Ho R.J. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS 19 (2005) 1617-1625